Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease

Simple item page
dc.catalogadordfo
dc.contributor.authorDesalegn, Hailemichael
dc.contributor.authorFarias Siel, Renata Francisca
dc.contributor.authorHudson, David
dc.contributor.authorIdalsoaga Ferrer, Francisco Javier
dc.contributor.authorCabrera, Daniel
dc.contributor.authorDíaz Piga, Luis Antonio
dc.contributor.authorArab Verdugo, Juan Pablo
dc.date.accessioned2024-11-20T18:28:37Z
dc.date.available2024-11-20T18:28:37Z
dc.date.issued2024
dc.description.abstractSteatotic liver disease (SLD), including metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD), is the primary cause of illness and mortality. In particular, MASLD affects more than 30% of the global population, while ALD accounts for 5.1% of all diseases and injuries worldwide. The SLD spectrum includes a variety of clinical conditions, from mild fatty liver and inflammation to different stages of liver fibrosis. Additionally, both conditions (MASLD and ALD) can be complicated by hepatocellular carcinoma (HCC), while around one-third of ALD patients can also develop at least one alcohol associated hepatitis (AH) episode. Both of these diseases are also associated with multiple extrahepatic complications, such as cardiovascular disease, chronic kidney disease, and malignancies. In MASLD, the rapid rise in global obesity and type 2 diabetes mellitus (T2DM) prevalence due to Westernized lifestyles has led to an increase in the prevalence of MASLD. Thus, the prevention and control of cardiometabolic risk factors (CMRFs) are the cornerstone of its treatment. Hypertension and atherogenic dyslipidemia are also important CMRFs associated with MASLD. Susceptible individuals with MASLD are adversely affected by even a small amount of alcohol consumption (though there is no agreed definition of a small amount), increasing the risk of severe outcomes and a faster progression of liver disease. This review explores factors that play a role in the development of SLD, especially focusing on the management of CMRFs and levels of alcohol use to prevent liver disease progression.
dc.description.funderChilean government through the Fondo Nacional de Ciencia y Tecnologia (FONDECYT)
dc.fechaingreso.objetodigital2024-11-20
dc.format.extent16 páginas
dc.fuente.origenWOS
dc.identifier.doi10.20517/mtod.2024.30
dc.identifier.eissn2769-6375
dc.identifier.urihttps://doi.org/10.20517/mtod.2024.30
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/88620
dc.identifier.wosidWOS:001319667100005
dc.information.autorucEscuela de Medicina; Farias Siel Renata Francisca; S/I; 1039497
dc.information.autorucEscuela de Medicina; Idalsoaga Ferrer Francisco Javier; S/I; 1017394
dc.information.autorucEscuela de Medicina; Diaz Piga Luis Antonio; 0000-0002-8540-4930; 179253
dc.information.autorucEscuela de Medicina; Arab Verdugo Juan Pablo; 0000-0002-8561-396X; 132745
dc.issue.numero3
dc.language.isoen
dc.nota.accesoContenido completo
dc.revistaMetabolism and Target Organ Damage
dc.rightsacceso abierto
dc.subjectAlcohol
dc.subjectAlcohol use disorder
dc.subjectMetabolic dysfunction-associated steatotic liver disease
dc.subjectAlcohol-associated liver disease (ALD)
dc.subject.ddc610
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePrevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease
dc.typereseña
dc.volumen4
sipa.codpersvinculados1039497
sipa.codpersvinculados1017394
sipa.codpersvinculados179253
sipa.codpersvinculados132745
sipa.trazabilidadWOS;2024-10-12
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
mtod4030_down.pdf
Size:
1.11 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas